Cargando…

Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

BACKGROUND: Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sruamsiri, Rosarin, Chaiyakunapruk, Nathorn, Pakakasama, Samart, Sirireung, Somtawin, Sripaiboonkij, Nintita, Bunworasate, Udomsak, Hongeng, Suradej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583808/ https://www.ncbi.nlm.nih.gov/pubmed/23379888 http://dx.doi.org/10.1186/1472-6963-13-45

Ejemplares similares

Cultural beliefs, utility values, and health technology assessment
por: Mahlich, Jörg, et al.
Publicado: (2018)

Effect of Hypertransfusion on Extramedullary Hematopoietic Compression Mass in Thalassemia Major: A Case Report
por: Emamhadi, Mohammadreza, et al.
Publicado: (2012)

No differences in hemostatic and endothelial activations between haploidentical and matched-donor hematopoietic stem cell transplantation in thalassemia disease
por: Lertthammakiat, Surapong, et al.
Publicado: (2020)

Quality of Reporting of Randomised Controlled Trials of Herbal Interventions in ASEAN Plus Six Countries: A Systematic Review
por: Pratoomsoot, Chayanin, et al.
Publicado: (2015)

Hematopoietic stem cell transplantation from an infected SARS-CoV2 donor sibling
por: Anurathapan, Usanarat, et al.
Publicado: (2020)

Association of zinc deficiency with infectious complications in pediatric hematopoietic stem cell transplantation patients
por: Suwanphoerung, Warangkhana, et al.
Publicado: (2022)

Increased Risk of Thai Childhood Acute Lymphoblastic Leukemia with the MiR196a2 T>C Polymorphism
por: Rakmanee, Sarinthorn, et al.
Publicado: (2017)

Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand
por: Sruamsiri, Rosarin, et al.
Publicado: (2015)

Clinical Effects of Thai Herbal Compress: A Systematic Review and Meta-Analysis
por: Dhippayom, Teerapon, et al.
Publicado: (2015)

Target Enrichment Metagenomics Reveals Human Pegivirus-1 in Pediatric Hematopoietic Stem Cell Transplantation Recipients
por: Ludowyke, Natali, et al.
Publicado: (2022)

Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
por: Adewoyin, Ademola Samson, et al.
Publicado: (2014)

Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis
por: Puttarak, Panupong, et al.
Publicado: (2017)

The Future of Gene Therapy for Transfusion-Dependent Beta-Thalassemia: The Power of the Lentiviral Vector for Genetically Modified Hematopoietic Stem Cells
por: Rattananon, Parin, et al.
Publicado: (2021)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis
por: Sruamsiri, Rosarin, et al.
Publicado: (2016)

Phosphoproteomic analysis of apoptotic hematopoietic stem cells from hemoglobin E/β-thalassemia
por: Ponnikorn, Saranyoo, et al.
Publicado: (2011)

Clinical Effects of Krachaidum (Kaempferia parviflora): A Systematic Review
por: Saokaew, Surasak, et al.
Publicado: (2016)

LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA
por: Sirachainan, Nongnuch, et al.
Publicado: (2020)

The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation
por: Park, Se Hoon, et al.
Publicado: (2004)

Screening for ELANE, HAX1 and GFI1 gene mutations in children with neutropenia and clinical characterization of two novel mutations in ELANE gene
por: Komvilaisak, Patcharee, et al.
Publicado: (2023)

Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach
por: Mahlich, Jörg, et al.
Publicado: (2019)

Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
por: Rojanaporn, Duangnate, et al.
Publicado: (2020)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

Respiratory and skin health among glass microfiber production workers: a cross-sectional study
por: Sripaiboonkij, Penpatra, et al.
Publicado: (2009)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

RARE-38. CLINICAL PRESENTATION OF MGA-NUTM1 FUSION TRANSCRIPT SARCOMA
por: Pongphitcha, Pongpak, et al.
Publicado: (2020)

Effect of vitamin A on intestinal mucosal injury in pediatric patients receiving hematopoietic stem cell transplantation and chemotherapy: a quasai-randomized trial
por: Pattanakitsakul, Ploy, et al.
Publicado: (2020)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

In Vitro Study of Ineffective Erythropoiesis in Thalassemia: Diverse Intrinsic Pathophysiological Features of Erythroid Cells Derived from Various Thalassemia Syndromes
por: Kaewsakulthong, Woratree, et al.
Publicado: (2022)

Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation
por: Asawapanumas, Thiti, et al.
Publicado: (2022)

2727. Risk factors and clinical outcomes of tuberculosis among hematopoietic stem cell transplant recipients in endemic country: A single-center, case-control study
por: Tanchotikul, Kamolchanok, et al.
Publicado: (2023)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

Prospective changes of cardiac iron and function by MR in pediatric thalassemia major patients treated with different chelators or not chelated
por: Meloni, Antonella, et al.
Publicado: (2015)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016)

Protection against Oxidative Stress in Beta Thalassemia/Hemoglobin E Erythrocytes by Inhibitors of Glutathione Efflux Transporters
por: Muanprasat, Chatchai, et al.
Publicado: (2013)

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ad8g017ipausv1tq6nebao52s